25 RS HB 423/HCS 1

1	AN ACT relating to prior authorization.
2	Be it enacted by the General Assembly of the Commonwealth of Kentucky:
3	→SECTION 1. A NEW SECTION OF KRS 304.17A-600 TO 304.17A-633 IS
4	CREATED TO READ AS FOLLOWS:
5	(1) As used in this section:
6	(a) "Covered health care service" means a health care service furnished or
7	proposed to be furnished to a covered person that is specifically available or
8	included as a covered benefit in the covered person's health benefit plan;
9	(b) "Electronic health record" has the same meaning as in 42 U.S.C. sec.
10	<u>17921, as amended;</u>
11	(c) "Evaluation period" means a twelve (12) month period of time for which a
12	health care provider's prior authorization experience is evaluated by an
13	insurer or private review agent;
14	(d) "Health care provider" has the same meaning as in KRS 304.17A-005,
15	except for purposes of this section the term includes, if practicing
16	independently, any:
17	1. Licensed clinical alcohol and drug counselor licensed under KRS
18	<u>Chapter 309;</u>
19	2. Licensed psychologist, licensed psychological practitioner, or certified
20	psychologist with autonomous functioning licensed or certified under
21	the provisions of KRS Chapter 319;
22	3. Licensed professional clinical counselor licensed under KRS Chapter
23	<u>335;</u>
24	4. Licensed marriage and family therapist licensed under KRS Chapter
25	<u>335;</u>
26	5. Licensed professional art therapist licensed under KRS Chapter 309;
27	and

1	6. Licensed clinical social worker licensed under KRS Chapter 335;
2	(e) "Health care provider group" means two (2) or more health care providers
3	that provide health care services within an entity that shares a common:
4	1. Group provider number; or
5	2. Tax identification number;
6	(f) "Health care service" has the same meaning as in KRS 304.17A-005,
7	except for purposes of this section the term:
8	1. Shall apply to health care providers as defined in this section; and
9	2. Does not include the provision of prescription drugs;
10	(g) "Interoperability standards" means the technical standards set forth in 45
11	<u>C.F.R. sec. 170.215, as amended;</u>
12	(h) "Participating provider":
13	1. Means a health care provider that has entered into a participating
14	provider contract; and
15	2. Includes a health care provider group if the insurer has elected to
16	offer an exemption to the health care provider group under subsection
17	(4)(b)2. of this section;
18	(i) "Participating provider contract" means a contract between a health care
19	provider, either directly or through a health care provider group, and an
20	insurer for the provision of health care services under a health benefit plan;
21	(j) "Utilization" means the number of claims submitted for a particular health
22	care service under a health benefit plan by a participating provider; and
23	(k) "Value-based care agreement" means a contractual agreement between a
24	health care provider, either directly or through a health care provider
25	group, and an insurer that:
26	1. Incentivizes or rewards providers based on one (1) or more of the
27	<u>following:</u>

1	a. Quality of care;
2	<u>b. Safety;</u>
3	<u>c. Patient outcomes;</u>
4	<u>d. Efficiency;</u>
5	e. Cost reduction; or
6	<u>f.</u> Other factors; and
7	2. May, but is not required to, include shared financial risk and rewards
8	based on performance metrics.
9	(2) An insurer or its private review agent shall not require a covered person,
10	authorized person, or participating provider to obtain a prior authorization for a
11	particular health care service under a health benefit plan if, at the time the health
12	care service was provided, the provider had a prior authorization exemption for
13	that particular health care service under a program offered under subsection (3)
14	of this section.
15	(3) Every insurer shall offer a program under which a participating provider may
16	qualify for an exemption from the requirement to obtain prior authorization for
17	any covered health care service that requires prior authorization.
18	(4) The program offered under subsection (3) of this section:
19	<u>(a) Shall:</u>
20	1. Provide that a participating provider, for an evaluation period
21	established by the insurer or private review agent, receive a prior
22	authorization exemption for a particular health care service if, during
23	the previous evaluation period, the provider met program terms and
24	conditions established by the insurer or private review agent that are
25	not in violation of this section;
26	2. Not condition a prior authorization exemption upon the provider
27	exceeding a ninety-three percent (93%) approval rate for prior

1		authorization requests submitted by the provider for that health care
2	÷	service during an evaluation period;
3	<u>3.</u>	Require the insurer or its private review agent to evaluate, on an
4		annual basis, whether a participating provider qualifies to receive a
5	i	prior authorization exemption for each covered health care service for
6		which the insurer requires prior authorization;
7	<u>4.</u>	Require each annual evaluation required under subparagraph 3. of
8	į	this paragraph to be conducted on:
9	9	a. For participating provider contracts that have a performance
10		period of one (1) year, the contract's renewal date; or
11		b. For participating provider contracts that have a performance
12		period of greater than one (1) year, the annual anniversary date
13		of the contract renewal;
14	<u>5.</u>	Require an insurer or its private review agent to notify each
15	i	participating provider that qualifies for a prior authorization
16	:	exemption within thirty (30) days after conducting the annual
17	:	evaluation required under subparagraph 3. of this paragraph;
18	<u>6.</u>	Require an insurer or its private review agent to make available to a
19	4	health care provider during the contracting process the requirements
20	i	that the provider must meet to participate in the program; and
21	<u>7.</u>	Comply with any administrative regulation promulgated under KRS
22	;	304.2-110 for, or as an aid to, the effectuation of this section; and
23	<u>(b) May:</u>	
24	<u>1.</u>	Offer a prior authorization exemption for any prescription drug;
25	<u>2.</u>	Offer a prior authorization exemption to a health care provider group
26	i	in lieu of each participating provider practicing within a health care
27	i	provider group;

1	3. Condition a participating provider's eligibility to participate in the
2	program on the provider satisfying one (1) or more of the following:
3	a. The provider has entered into, either directly or through a health
4	care provider group, a value-based care agreement with the
5	<u>insurer;</u>
6	b. The provider has been a participating provider for a minimum
7	period of time established by the insurer or private review agent,
8	except an established minimum period of time shall not be more
9	than one (1) year; or
10	<u>c. The provider:</u>
11	<i>i.</i> Complies with interoperability standards; and
12	ii. Has entered into, either directly or through a health care
13	provider group, an electronic health record access
14	agreement with the insurer or private review agent; and
15	4. Provide that a participating provider shall not qualify for a prior
16	authorization exemption for any particular health care service unless
17	the provider's utilization for that health care service during the
18	previous evaluation period meets any utilization requirement
19	established by the insurer or private review agent, except an
20	established utilization requirement shall not:
21	a. Require a minimum utilization of more than twenty-four (24); or
22	b. Impose a maximum utilization of less than one hundred ten
23	percent (110%) of the participating provider's utilization for that
24	particular health care service during the previous evaluation
25	period; and
26	5. Provide that an insurer or its private review agent may revoke a
27	participating provider's prior authorization exemption for any

1	particular health care service, or suspend or revoke a participating
2	provider's participation in the program, if:
3	a. The insurer or private review agent has evidence that the
4	provider has engaged in fraud or abuse; or
5	<u>b. The provider's utilization meets or exceeds a maximum</u>
6	utilization imposed under subparagraph 4.b. of this paragraph.
7	(5) If an insurer or its private review agent determines that a participating provider is
8	eligible to participate in the program offered under subsection (3) of this section,
9	the insurer or private review agent shall send a notice to the provider that
10	includes:
11	(a) A statement that the provider is eligible to participate in the program; and
12	(b) A list of each health care service that is subject to the elimination of prior
13	authorization requirements under the program.
14	(6) For all forms and notices sent to a participating provider in accordance with this
15	section, or any administrative regulations promulgated under KRS 304.2-110 for,
16	or as an aid to, the effectuation of this section, the insurer or its private review
17	agent shall:
18	(a) Provide a process for the provider to designate and update the provider's
19	preferred manner for receiving the forms and notices; and
20	(b) Send the forms and notices to the provider in the manner designated under
21	paragraph (a) of this subsection.
22	(7) Nothing in this section shall be construed to:
23	(a) Prevent an insurer or its private review agent from requesting a health care
24	provider to provide additional information about a health care service
25	rendered to a covered person; or
26	(b) Require coverage of a noncovered health care service under a covered
27	person's health benefit plan.

1	→ SEC	TION 2. A NEW SECTION OF KRS 304.17A-600 TO 304.17A-633 IS
2	CREATED T	O READ AS FOLLOWS:
3	<u>The commiss</u>	<u>ioner shall:</u>
4	<u>(1) (a) Sı</u>	ıbmit a written report not later than September 30 of each year to the
5	Le	egislative Research Commission for referral to the Interim Joint
6	<u>Ca</u>	ommittees on Banking and Insurance and Health Services relating to
7	<u>pr</u>	ior authorization in the provision of health care benefits under this
8	<u>ch</u>	napter.
9	<u>(b) T</u>	he report required under paragraph (a) of this subsection shall include:
10	<u>1.</u>	Information relating to the implementation and effectuation of
11		Section 1 of this Act;
12	<u>2.</u>	The number of insurers and private review agents offering a program
13		required under Section 1 of this Act;
14	<u>3.</u>	The number of providers, by provider group, specialty, and county,
15		participating in one (1) or more programs offered under Section 1 of
16		this Act;
17	<u>4.</u>	A list of health care services, which shall include a description and
18		CPT code for each service, for which exemptions have been granted
19		under the programs required under Section 1 of this Act;
20	<u>5.</u>	The number of programs offered under Section 1 of this Act, which
21		shall include:
22		a. The number of programs that grant exemptions for one (1) or
23		more prescription drugs; and
24		b. A list of the drugs for which exemptions are granted under a
25		program reported under subdivision a. of this subparagraph; and
26	<u>6.</u>	With respect to any health insurance policy, certificate, plan, or
27		contract required to comply with KRS 304.17A-600 to 304.17A-633:

1	a. A list of all services, procedures, and other treatments, including
2	prescription drugs, that require prior authorization;
3	b. The percentage of prior authorization requests for nonurgent
4	<u>health care services in aggregate and by specific service,</u>
5	procedure, prescription drug, and other treatment:
6	i. That were approved without an extension;
7	ii. For which the review was extended and the request
8	approved; and
9	iii. That were denied;
10	c. The percentage of prior authorization requests for urgent health
11	care services that were:
12	i. Approved; and
13	<u>ii. Denied; and</u>
14	d. The average and median time between submission of prior
15	authorization requests and decisions for:
16	i. Nonurgent health care services; and
17	ii. Urgent health care services;
18	(2) Provide the Interim Joint Committees on Banking and Insurance and Health
19	Services with a detailed briefing, upon request, to discuss and explain any report
20	submitted under subsection (1) of this section; and
21	(3) Promulgate any administrative regulation, including an emergency
22	administrative regulation, in accordance with KRS Chapter 13A that the
23	commissioner deems necessary to implement the provisions of this section.
24	→Section 3. KRS 304.17A-605 is amended to read as follows:
25	(1) (a) Except as provided in paragraph (b) of this subsection, KRS 304.17A-600,
26	304.17A-603, 304.17A-605, 304.17A-607, 304.17A-609, 304.17A-611,
27	304.17A-613, and 304.17A-615 set forth the requirements and procedures

1		regarding utilization review and shall apply to:
2		<u>1.[(a)]</u> Any insurer or its private review agent that provides or performs
3		utilization review in connection with a health benefit plan or a limited
4		health service benefit plan; and
5		<u>2.[(b)]</u> Any private review agent that performs utilization review
6		functions on behalf of any person providing or administering health
7		benefit plans or limited health service benefit plans.
8		(b) Section 1 of this Act sets forth additional requirements for prior
9		authorization and shall apply to:
10		1. Any insurer or its private review agent that provides or performs
11		utilization review in connection with a health benefit plan; and
12		2. Any private review agent that performs utilization review functions on
13		behalf of any person providing and administering health benefit plans.
14	(2)	Where an insurer or its agent provides or performs utilization review, and in all
15		instances where internal appeals as set forth in KRS 304.17A-617 are involved, the
16		insurer or its agent shall be responsible for:
17		(a) Monitoring all utilization reviews and internal appeals carried out by or on
18		behalf of the insurer;
19		(b) Ensuring that all requirements of KRS 304.17A-600 to 304.17A-633 are met;
20		(c) Ensuring that all administrative regulations promulgated in accordance with
21		KRS 304.17A-609, 304.17A-613, and 304.17A-629 are complied with; and
22		(d) Ensuring that appropriate personnel have operational responsibility for the
23		performance of the insurer's utilization review plan.
24	(3)	A private review agent that operates solely under contract with the federal
25		government for utilization review or patients eligible for hospital services under
26		Title XVIII of the Social Security Act shall not be subject to the registration
27		requirements set forth in KRS 304.17A-607, 304.17A-609, and 304.17A-613.

25 RS HB 423/HCS 1

1		→Section 4. KRS 304.17A-611 is amended to read as follows:
2	(1)	A utilization review decision shall not retrospectively deny coverage for health care
3		services provided to a covered person when prior approval has been obtained from
4		the insurer or its designee for those services, unless the approval was based upon
5		fraudulent, materially inaccurate, or misrepresented information submitted by the
6		covered person, authorized person, or the provider.
7	(2)	An insurer of a health benefit plan shall not require or conduct a prospective or
8		concurrent review for a prescription drug:
9		(a) That:
10		1. Is used in the treatment of alcohol or opioid use disorder; and
11		2. Contains Methadone, Buprenorphine, an opioid antagonist, or
12		Naltrexone; or
13		(b) That was approved before January 1, 2022, by the United States Food and
14		Drug Administration for the mitigation of opioid withdrawal symptoms.
15	<u>(3)</u>	Notwithstanding any other law to the contrary:
16		(a) An insurer or its private review agent shall not conduct a retrospective
17		review that is based solely on a participating provider having a prior
18		authorization exemption under a program offered under subsection (3) of
19		Section 1 of this Act except to determine if the provider continues to qualify
20		for an exemption; and
21		(b) The timeframes for rendering a utilization review decision under KRS
22		304.17A-607 shall not apply to a retrospective review conducted for the
23		purpose of determining if a participating provider qualifies for an initial or
24		continuing prior authorization exemption under a program offered under
25		subsection (3) of Section 1 of this Act.
26		→SECTION 5. A NEW SECTION OF KRS CHAPTER 205 IS CREATED TO

Page 10 of 13

1	<u>The comm</u>	nissioner of the Department for Medicaid Services shall:
2	<u>(1) (a)</u>	Submit a written report not later than September 30 of each year to the
3		Legislative Research Commission for referral to the Interim Joint
4		Committees on Banking and Insurance and Health Services relating to
5		prior authorization in the provision of Medicaid benefits in Kentucky.
6	<u>(b)</u>	The report required under paragraph (a) of this subsection shall include the
7		following, categorized by Medicaid managed care organization and fee for
8		<u>service:</u>
9		1. A list of all services, procedures, and other treatments, including
10		prescription drugs, that require prior authorization;
11		2. The percentage of prior authorization requests for nonurgent health
12		<u>care services in aggregate and by specific service, procedure,</u>
13		prescription drug, and other treatment:
14		a. That were approved without an extension;
15		b. For which the review was extended and the request approved;
16		and
17		<u>c. That were denied;</u>
18		3. The percentage of prior authorization requests for urgent health care
19		services that were:
20		a. Approved; and
21		b. Denied; and
22		4. The average and median time between submission of prior
23		authorization requests and decisions for:
24		a. Nonurgent health care services; and

25 b. Urgent health care services;

- (2) Provide the Interim Joint Committees on Banking and Insurance and Health 26
- Services with a detailed briefing, upon request, to discuss and explain any report 27

25 RS HB 423/HCS 1

1 <u>submitted under subsection (1) of this section; and</u>

2 (3) Promulgate any administrative regulation, including an emergency
 3 administrative regulation, in accordance with KRS Chapter 13A that the
 4 commissioner deems necessary to implement the provisions of this section.

5 \rightarrow Section 6. KRS 205.536 is amended to read as follows:

- 6 (1) <u>Except as provided in subsection (4) of this section</u>, a Medicaid managed care
 7 organization shall have a utilization review plan, as defined in KRS 304.17A-600,
 8 that meets the requirements established in 42 C.F.R. pts. 431, 438, and 456. If the
 9 Medicaid managed care organization utilizes a private review agent, as defined in
 10 KRS 304.17A-600, the agent shall comply with all applicable requirements of KRS
 11 304.17A-600 to 304.17A-633.
- 12 (2) In conducting utilization reviews for Medicaid benefits, each Medicaid managed
 13 care organization shall use the medical necessity criteria selected by the Department
 14 of Insurance pursuant to KRS 304.38-240, for making determinations of medical
 15 necessity and clinical appropriateness pursuant to the utilization review plan
 16 required by subsection (1) of this section.
- 17 (3) To the extent consistent with the federal regulations referenced in subsection (1) of
 18 this section, the Department for Medicaid Services or any managed care
 19 organization contracted to provide Medicaid benefits pursuant to KRS Chapter 205
 20 shall not require or conduct a prospective or concurrent review, as defined in KRS
 21 304.17A-600, for a prescription drug:
- 22 (a) That:
- 23

1. Is used in the treatment of alcohol or opioid use disorder; and

- 24 2. Contains Methadone, Buprenorphine, an opioid antagonist, or
 25 Naltrexone; or
- (b) That was approved before January 1, 2022, by the United States Food and
 Drug Administration for the mitigation of opioid withdrawal symptoms.

1	(4) Nothing in this chapter shall be construed to require, with respect to the
2	administration and provision of Medicaid benefits pursuant to this chapter, the
3	Department for Medicaid Services, any managed care organization contracted to
4	provide Medicaid benefits pursuant to this chapter, including any private review
5	agent utilized by the Medicaid managed care organization, or the state's medical
6	assistance program to comply with Section 1 of this Act.
7	Section 7. Sections 1 to 4 of this Act apply to contracts delivered, entered,
8	renewed, extended, or amended on or after January 1, 2027.
9	Section 8. Section 5 of this Act takes effect January 1, 2026.
10	→ Section 9. Sections 1, 2, 3, 4, 6, and 7 of this Act take effect January 1, 2027.